Aspire Biopharma Holdings (ASBP) Preferred Stock Liabilities (2022 - 2024)

Aspire Biopharma Holdings (ASBP) has 3 years of Preferred Stock Liabilities data on file, last reported at $6.7 million in Q4 2024.

• On a quarterly basis, Preferred Stock Liabilities fell 66.49% year-over-year to $6.7 million in Q4 2024; TTM through Dec 2024 was $6.7 million, a 66.49% decrease from a year earlier, with the FY2024 full-year figure at $6.7 million, down 66.49% from the prior year.
• Preferred Stock Liabilities for Q4 2024 stood at $6.7 million, up from $6.5 million in the prior quarter.
• Over the last five years, Preferred Stock Liabilities for ASBP reached as high as $302.2 million in Q1 2023 and fell as low as $6.5 million in Q2 2024.
• Historically, Preferred Stock Liabilities has averaged $143.7 million across 3 years, with a median of $20.1 million in 2024.
• On a YoY basis, Preferred Stock Liabilities climbed as much as 2.55% in 2023 and fell as far as 93.37% in 2023.
• Year by year, Preferred Stock Liabilities stood at $299.0 million in 2022, then tumbled by 93.34% to $19.9 million in 2023, then slumped by 66.49% to $6.7 million in 2024.
• Per Business Quant data, the three most recent Preferred Stock Liabilities figures were $6.7 million in Q4 2024, $6.5 million in Q2 2024, and $20.1 million in Q1 2024.